Browse News
Filter News
Found 5 articles
-
Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders
12/13/2023
Encellin announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
-
Cardiometabolic disease is an overlooked therapeutic space that represents a huge and growing need as the global population ages, according to panelists speaking at Biotech Showcase.
-
Encellin Closes $5.9M Seed Financing Co-Led by Khosla Ventures and SV Latam Capital
8/5/2021
Encellin, a personalized regenerative medicine biotech company developing novel cell-based approaches to deliver sustained therapies with a single implant, announced the closing of a $5.9M Seed financing round.
-
Grace Wei, Ph.D., who founded Encellin in 2016 with co-founder Crystal Nyitray, Ph.D., shared some of her lessons during a recent Innovation Centre Denmark, Silicon Valley presentation for would-be biotech entrepreneurs.
-
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
1/10/2020
Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic G-NK (FcRγ-deficient Natural Killer) cell therapy to treat multiple cancers, and Lonza today announced a strategic partnership